| Title |
Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease
|
|---|---|
| Published in |
Pediatric Nephrology, September 2017
|
| DOI | 10.1007/s00467-017-3787-0 |
| Pubmed ID | |
| Authors |
Sahar Fathallah-Shaykh, Dorota Drozdz, Joseph Flynn, Randall Jenkins, Katherine Wesseling-Perry, Sarah J. Swartz, Craig Wong, Beverly Accomando, Gerald F. Cox, Bradley A. Warady |
| Abstract |
Treatment for hyperphosphatemia in chronic kidney disease (CKD) involves dietary control of phosphorus intake, dialysis, and treatment with oral phosphate binders, none of which were approved by the Federal Food and Drug Administration in pediatric patients at the time of this study. This was a phase 2, multicenter study (NCT01574326) with a 2-week, randomized, placebo-controlled, fixed-dose period (FDP) followed by a 6-month, single-arm, open-label, dose-titration period (DTP), with the aim to evaluate the safety and efficacy of sevelamer carbonate (SC) in hyperphosphatemic pediatric patients with CKD. Following a 2-4 week screening phase, pediatric patients with a serum phosphorus level higher than age-appropriate levels were randomized to receive either SC or placebo as powder/tablets in 0.4-1.6 g doses, based on body surface area. The primary efficacy outcome was the change in serum phosphorus from baseline to end of the FDP in the SC versus placebo arms (analysis of covariance). The secondary outcome was mean change in serum phosphorus from baseline to end of DTP by treatment group and overall. Treatment-emergent/serious adverse events (AEs) were recorded. Of 101 enrolled patients (29 centers), 66 completed the study. The majority of patients were adolescents (74%; mean age 14.1 years) and on dialysis (77%). Renal transplant was the main reason for discontinuation. SC significantly reduced serum phosphorus from baseline levels (7.16 mg/dL) during the FDP compared to placebo (least square mean difference - 0.90 mg/dL, p = 0.001) and during the DTP (- 1.18 mg/dL, p < 0.0001). The safety and tolerability of SC and placebo were similar during the FDP, with patients in both groups reporting mild/moderate gastrointestinal AEs during the DTP. Sevelamer carbonate significantly lowered serum phosphorus levels in hyperphosphatemic children with CKD, with no serious safety concerns identified. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 10% |
| Iceland | 1 | 10% |
| Brazil | 1 | 10% |
| Venezuela, Bolivarian Republic of | 1 | 10% |
| United States | 1 | 10% |
| Mexico | 1 | 10% |
| Unknown | 4 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 60% |
| Science communicators (journalists, bloggers, editors) | 2 | 20% |
| Practitioners (doctors, other healthcare professionals) | 1 | 10% |
| Scientists | 1 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 74 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 11 | 15% |
| Researcher | 8 | 11% |
| Student > Master | 8 | 11% |
| Student > Postgraduate | 7 | 9% |
| Student > Doctoral Student | 5 | 7% |
| Other | 15 | 20% |
| Unknown | 20 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 31% |
| Nursing and Health Professions | 9 | 12% |
| Social Sciences | 3 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Agricultural and Biological Sciences | 2 | 3% |
| Other | 10 | 14% |
| Unknown | 24 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 November 2020.
All research outputs
#4,779,093
of 23,310,485 outputs
Outputs from Pediatric Nephrology
#784
of 3,619 outputs
Outputs of similar age
#82,282
of 316,730 outputs
Outputs of similar age from Pediatric Nephrology
#18
of 71 outputs
Altmetric has tracked 23,310,485 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,619 research outputs from this source. They receive a mean Attention Score of 5.0. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 316,730 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.